CLOs on the Move

Olema Pharmaceuticals

www.olemapharma.com

 
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

RenalytixAI

Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease.

MD Communications Group

MD Communications Group is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a Westfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ecopia BioSciences

Ecopia BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.